[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI1012890A2 - composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit - Google Patents

composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit

Info

Publication number
BRPI1012890A2
BRPI1012890A2 BRPI1012890A BRPI1012890A BRPI1012890A2 BR PI1012890 A2 BRPI1012890 A2 BR PI1012890A2 BR PI1012890 A BRPI1012890 A BR PI1012890A BR PI1012890 A BRPI1012890 A BR PI1012890A BR PI1012890 A2 BRPI1012890 A2 BR PI1012890A2
Authority
BR
Brazil
Prior art keywords
composition
immunogenic composition
kit
preparing
aqueous adjuvant
Prior art date
Application number
BRPI1012890A
Other languages
English (en)
Inventor
Ingrid Lemoine Dominique
Henderickx Veronique
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012890(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BRPI1012890A2 publication Critical patent/BRPI1012890A2/pt
Publication of BRPI1012890B1 publication Critical patent/BRPI1012890B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1012890-5A 2009-06-10 2010-06-08 Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit BRPI1012890B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0910046.2 2009-06-10
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
PCT/EP2010/058017 WO2010142685A1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (2)

Publication Number Publication Date
BRPI1012890A2 true BRPI1012890A2 (pt) 2018-02-27
BRPI1012890B1 BRPI1012890B1 (pt) 2022-03-22

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012890-5A BRPI1012890B1 (pt) 2009-06-10 2010-06-08 Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit

Country Status (31)

Country Link
US (2) US20120087976A1 (pt)
EP (1) EP2440242B1 (pt)
JP (3) JP5647677B2 (pt)
KR (1) KR101473686B1 (pt)
CN (2) CN104367997B (pt)
AU (1) AU2010257538B2 (pt)
BR (1) BRPI1012890B1 (pt)
CA (1) CA2764421C (pt)
CL (1) CL2011003113A1 (pt)
CO (1) CO6440528A2 (pt)
CY (1) CY1115522T1 (pt)
DK (1) DK2440242T3 (pt)
DO (1) DOP2011000346A (pt)
EA (1) EA024074B1 (pt)
ES (1) ES2494442T3 (pt)
GB (1) GB0910046D0 (pt)
HR (1) HRP20140792T1 (pt)
IL (1) IL216231A0 (pt)
MA (1) MA33412B1 (pt)
MX (1) MX2011013162A (pt)
MY (1) MY159819A (pt)
NZ (1) NZ596503A (pt)
PE (1) PE20120319A1 (pt)
PL (1) PL2440242T3 (pt)
PT (1) PT2440242E (pt)
RS (1) RS53550B1 (pt)
SG (1) SG176638A1 (pt)
SI (1) SI2440242T1 (pt)
SM (1) SMT201400134B (pt)
UA (1) UA104888C2 (pt)
WO (1) WO2010142685A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028278T2 (en) 2009-06-10 2016-12-28 Chugai Pharmaceutical Co Ltd Tetracyclic compound
SG187614A1 (en) 2010-08-20 2013-03-28 Chugai Pharmaceutical Co Ltd Composition containing tetracyclic compound
SG190937A1 (en) * 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
US10434167B2 (en) * 2014-03-25 2019-10-08 The Government Of The United States As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
CA3140565C (en) 2014-04-25 2022-10-11 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
MX2017009246A (es) 2015-01-16 2017-10-12 Chugai Pharmaceutical Co Ltd Farmaco de combinacion.
WO2017079582A1 (en) 2015-11-06 2017-05-11 Adjuvance Technologies, Inc. Triterpene saponin analogues
MX2019006728A (es) * 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
CA3075822A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
CN111372604A (zh) 2017-12-01 2020-07-03 葛兰素史密丝克莱恩生物有限公司 皂苷提取
KR102635225B1 (ko) 2018-09-04 2024-02-07 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 제조방법
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2024190865A1 (ja) * 2023-03-15 2024-09-19 ユナイテッド・イミュニティ株式会社 脂質粒子

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
PT812593E (pt) * 1993-03-23 2002-01-30 Smithkline Beecham Biolog Vacinas contendo monofosforil-lipido a 3-o-desacilado na sua composicao
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
IL137442A0 (en) 1998-02-05 2001-07-24 Smithkline Beecham Biolog Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
PT1075276E (pt) * 1998-05-07 2008-01-22 Corixa Corp Composição adjuvante e métodos para sua utilização
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP2008521385A (ja) * 2004-11-29 2008-06-26 長春華普生物技術有限公司 アジュバントとしてのCpG含有一本鎖デオキシヌクレオチド
ATE462444T1 (de) * 2005-06-27 2010-04-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ES2398492T3 (es) 2007-01-15 2013-03-19 Glaxosmithkline Biologicals Sa Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
JP5391080B2 (ja) 2007-01-15 2014-01-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CA2687632C (en) * 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
SI2440242T1 (sl) 2014-09-30
US20120087976A1 (en) 2012-04-12
CL2011003113A1 (es) 2012-08-31
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
CA2764421A1 (en) 2010-12-16
EP2440242B1 (en) 2014-06-25
MY159819A (en) 2017-02-15
EA024074B1 (ru) 2016-08-31
PL2440242T3 (pl) 2014-11-28
RS53550B1 (en) 2015-02-27
CY1115522T1 (el) 2017-01-04
SMT201400134B (it) 2014-11-10
CN104367997A (zh) 2015-02-25
JP5647677B2 (ja) 2015-01-07
BRPI1012890B1 (pt) 2022-03-22
IL216231A0 (en) 2012-01-31
CN104367997B (zh) 2019-01-22
CN102458457B (zh) 2015-05-20
CO6440528A2 (es) 2012-05-15
CN102458457A (zh) 2012-05-16
JP2016193912A (ja) 2016-11-17
NZ596503A (en) 2013-08-30
GB0910046D0 (en) 2009-07-22
WO2010142685A1 (en) 2010-12-16
KR20120031497A (ko) 2012-04-03
KR101473686B1 (ko) 2014-12-18
JP2015042646A (ja) 2015-03-05
SG176638A1 (en) 2012-01-30
MX2011013162A (es) 2012-01-30
ES2494442T3 (es) 2014-09-15
JP2012529464A (ja) 2012-11-22
PT2440242E (pt) 2014-08-29
AU2010257538A1 (en) 2011-12-08
EP2440242A1 (en) 2012-04-18
US20180021417A1 (en) 2018-01-25
JP6261647B2 (ja) 2018-01-17
DOP2011000346A (es) 2012-01-15
JP5977789B2 (ja) 2016-08-24
EA201190286A1 (ru) 2012-06-29
DK2440242T3 (da) 2014-09-01
HRP20140792T1 (hr) 2014-10-10
PE20120319A1 (es) 2012-04-16
CA2764421C (en) 2016-12-06
AU2010257538B2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
BRPI1012890A2 (pt) composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit
BRPI0916884A2 (pt) composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit
BR112013014598A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0909820A2 (pt) Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI0918349A2 (pt) Processo para preparar dióxido de divinilareno
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0813307A2 (pt) Composição imunogênica, vacina, e, processo para fabricar a vacina
BR112012004807A2 (pt) vacina para pcsk9
BRPI0924622A2 (pt) composições para tratamento de tecidos, processo de fabricação, e método de uso.
BRPI0919192A2 (pt) Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional
BRPI1014606A2 (pt) Maltotriosil transferase, processo para produção e uso da mesma
BRPI1013561A8 (pt) processo para a preparação de alogliptina
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0911815A2 (pt) estrutura de multifilme, estrutura de envelope feita de uma estrutura de multifilme, uso de uma estrutura de multifilme e processo para preparar uma estrutura de multifilme
BRPI0922984A2 (pt) processo para preparar trietanolamina pura
BRPI1005919A2 (pt) composição imunogênica
BRPI1011639A2 (pt) composição anticongelante, e, método para aumentar a estabilidade térmica de uma composição anticongelante
BRPI1008484A2 (pt) codificador, decodificador e método para os mesmos
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BRPI1013051A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para fazer uma composição imunogênica, e, kit.
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BR112012008202A2 (pt) processo de preparação de uma composição, componentes e uso da composição
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.